Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Blinklab Limited ( (AU:BB1) ).
BlinkLab Limited has announced the onboarding of the University of Pennsylvania Perelman School of Medicine as the third clinical site for its FDA 510(k) diagnostic trial aimed at autism detection. This collaboration brings together the expertise of renowned autism researchers Dr. Heather Nuske and Prof. David Mandel, enhancing BlinkLab’s efforts to gain FDA clearance for its smartphone-based diagnostic tool, BlinkLab Dx 1. The trial, which is entering its main study phase, aims to recruit up to 900 participants and is expected to be completed by Q2 2026. The partnership with such a prestigious institution underscores BlinkLab’s commitment to scientific rigor and clinical excellence, potentially impacting the speed and accuracy of autism diagnoses.
More about Blinklab Limited
BlinkLab Limited is a leading digital healthcare company specializing in AI-powered diagnostics. The company focuses on developing innovative diagnostic tools, particularly in the field of autism, and is currently conducting an FDA 510(k) trial for its BlinkLab Dx 1 platform.
Average Trading Volume: 245,991
Technical Sentiment Signal: Buy
For detailed information about BB1 stock, go to TipRanks’ Stock Analysis page.